{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Women-Only&page=32",
    "query": {
      "intervention": "Women-Only",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 1543,
    "total_pages": 155,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Women-Only&page=33&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Women-Only&page=31&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T07:32:31.361Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01640912",
      "title": "Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cicatrix",
        "Scar Prevention"
      ],
      "interventions": [
        {
          "name": "RXI-109",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RXi Pharmaceuticals, Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 50 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2012-06",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2014-09-17",
      "last_synced_at": "2026-10-17T07:32:31.361Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01640912"
    },
    {
      "nct_id": "NCT07195071",
      "title": "Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hereditary Cancer Syndrome"
      ],
      "interventions": [
        {
          "name": "Natera empower comprehensive hereditary cancer panel",
          "type": "DEVICE"
        },
        {
          "name": "Obstetrical carrier screening",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 1000,
      "start_date": "2026-02-12",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-10-17T07:32:31.361Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07195071"
    },
    {
      "nct_id": "NCT00394030",
      "title": "Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "GSK716155 subcutaneous injections",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 63,
      "start_date": "2006-10-16",
      "completion_date": "2007-03-20",
      "has_results": false,
      "last_update_posted_date": "2017-09-11",
      "last_synced_at": "2026-10-17T07:32:31.361Z",
      "location_count": 6,
      "location_summary": "Long Beach, California • Walnut Creek, California • Miramar, Florida + 3 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Morrisville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00394030"
    },
    {
      "nct_id": "NCT02431273",
      "title": "Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus (HIV) Prophylaxis"
      ],
      "interventions": [
        {
          "name": "TDF IVR",
          "type": "DRUG"
        },
        {
          "name": "TDF-FTC IVR",
          "type": "DRUG"
        },
        {
          "name": "TDF-FTC-MVC IVR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Auritec Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2015-06",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2019-07-02",
      "last_synced_at": "2026-10-17T07:32:31.361Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431273"
    },
    {
      "nct_id": "NCT01519687",
      "title": "Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperuricemia",
        "Gout"
      ],
      "interventions": [
        {
          "name": "levotofisopam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmos",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2012-01",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2012-01-27",
      "last_synced_at": "2026-10-17T07:32:31.361Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01519687"
    },
    {
      "nct_id": "NCT00640458",
      "title": "Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-menopausal Women With Female Sexual Arousal Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Female Sexual Arousal Disorder"
      ],
      "interventions": [
        {
          "name": "Sildenafil 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2004-04",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2021-02-01",
      "last_synced_at": "2026-10-17T07:32:31.361Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00640458"
    },
    {
      "nct_id": "NCT07645235",
      "title": "A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urinary Tract Infections"
      ],
      "interventions": [
        {
          "name": "Gepotidacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 8,
      "start_date": "2026-07-23",
      "completion_date": "2027-05-17",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-17T07:32:31.361Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07645235"
    },
    {
      "nct_id": "NCT04290208",
      "title": "A Comparison of IV Versus PO Acetaminophen Postoperatively for Opioid Consumption After Cesarean Section",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Postoperative Pain",
        "Cesarean Section",
        "Acetaminophen"
      ],
      "interventions": [
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Main Line Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 130,
      "start_date": "2019-08-22",
      "completion_date": "2020-06-23",
      "has_results": false,
      "last_update_posted_date": "2020-02-28",
      "last_synced_at": "2026-10-17T07:32:31.361Z",
      "location_count": 1,
      "location_summary": "Wynnewood, Pennsylvania",
      "locations": [
        {
          "city": "Wynnewood",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04290208"
    },
    {
      "nct_id": "NCT04019652",
      "title": "The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypertension",
        "Mineralocorticoid Receptor Antagonist"
      ],
      "interventions": [
        {
          "name": "CS-3150",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching moxifloxacin tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching CS-3150",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 55,
      "start_date": "2015-11-19",
      "completion_date": "2015-12-23",
      "has_results": false,
      "last_update_posted_date": "2019-07-15",
      "last_synced_at": "2026-10-17T07:32:31.361Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04019652"
    },
    {
      "nct_id": "NCT02980848",
      "title": "Assessing Breast Density's Value in Imaging - A Comparative Effectiveness Study",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Screening digital mammography",
          "type": "OTHER"
        },
        {
          "name": "Screening digital breast tomosynthesis",
          "type": "OTHER"
        },
        {
          "name": "Screening breast magnetic resonance imaging",
          "type": "OTHER"
        },
        {
          "name": "Diagnostic mammography",
          "type": "OTHER"
        },
        {
          "name": "Pre-operative breast magnetic resonance imaging",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 89 Years · Female only"
      },
      "enrollment_count": 1341172,
      "start_date": "2016-09",
      "completion_date": "2022-02",
      "has_results": false,
      "last_update_posted_date": "2021-11-17",
      "last_synced_at": "2026-10-17T07:32:31.361Z",
      "location_count": 7,
      "location_summary": "Davis, California • San Francisco, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02980848"
    }
  ]
}